Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00744692
Other study ID # Pro00008753
Secondary ID
Status Completed
Phase Phase 1
First received August 28, 2008
Last updated July 23, 2014
Start date October 2008
Est. completion date April 2014

Study information

Verified date July 2014
Source Duke University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The primary objective is to determine the feasibility of attaining acceptable rates of donor cell engraftment (>25% donor chimerism at 180 days) following reduced intensity conditioning (RIC) regimens in pediatric patients < 21 years receiving cord blood transplantation for non-malignant disorders.


Description:

Myeloablative doses of chemotherapy and/or radiation therapy are employed with the primary purpose of eradicating malignant cells. Additionally, these regimens exert varying degree of immunosuppression/immunoablation that aids in reducing the likelihood of rejection by host hematopoietic cells. However, myeloablative /immunoablative regimens have also been associated with significant regimen related toxicity (RRT) and regimen related mortality (RRM) that may cause death in up to 20% of patients and significantly higher rate of severe organ dysfunction or failure. While most of these RRT occur typically in the first 100 days [ e.g. VOD (veno occlusive disease), pulmonary or intracranial hemorrhage, multiorgan failure (MOF)], there are significant long term toxicities of TBI and/or chemotherapy including growth impairment, gonadal dysfunction/failure, hypothyroidism, cataracts, neurocognitive impairment, and second malignancies.

The primary objective is to determine the feasibility of attaining acceptable rates of donor cell engraftment (>25% donor chimerism at 180 days) following reduced intensity conditioning (RIC) regimens in pediatric patients < 21 years receiving cord blood transplantation for non-malignant disorders.

The secondary objectives are:

- To describe the pace of neutrophil and platelet recovery

- To evaluate the pace of immune reconstitution.

- To determine the treatment related mortality, overall survival and disease free survival by days 100 and 180 post-transplant

- To describe incidence of acute Graft Versus Host Disease (GVHD) (II - IV) and chronic extensive GVHD

- To describe the incidence of grade 3-4 organ toxicity

- To evaluate long-term complications, such as sterility, endocrinopathy, and growth failure

- To evaluate the incidence of late graft failures at 2 years post-transplant


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date April 2014
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group N/A to 21 Years
Eligibility Inclusion Criteria:

- 0-21 years of age with a diagnosis of a immunodeficiency, congenital marrow failure syndrome, inborn error of metabolism, or hereditary anemia

- Appropriately matched related or unrelated umbilical cord blood unit with a cell dose = 3 x 10e7cells/kg

- Performance score (lansky or karnofsky) greater than or equal to 70

- Adequate organ function (Creatinine = 2.0 mg/dl and creatinine clearance = 50 ml/min/1.73 m2; Hepatic transaminases (ALT/AST) = 4 x normal; Shortening fraction >26% or ejection fraction >40% or > 80% of normal value for age; Pulmonary function tests demonstrating CVC or FEV1/FVC of >60% of predicted for age.)

- Informed consent

- Not pregnant or breast feeding

- Minimum life expectancy of at least 6 months

- HIV negative

- No uncontrolled infections at the time of cytoreduction

- Disease specific inclusion criteria

Exclusion Criteria:

- Patients with hemoglobinopathies > 3 years of age

- UCB unit with a total nucleated cell count < 3 x 10e7/kg or > 2 antigen mismatching

- Available HLA-matched related living donor able to donate without previous UCB donation

- Allogeneic hematopoietic stem cell transplant within the previous 6 months

- Any active malignancy, MDS, or any history of malignancy

- Severe acquired aplastic anemia

- DLCO < 60% of normal value for age; requirement for supplemental oxygen

- Uncontrolled bacterial, viral or fungal infection (currently taking medication and progression of clinical symptoms)

- Pregnancy or nursing mother

- HIV/HTLV seropositive, Hep B surface antigen positive, or HCV RNA positive by PCR

- Any condition that precludes serial follow-up

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Biological:
Unrelated Umbilical Cord Blood Transplant
Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
Drug:
Reduced Intensity Conditioning


Locations

Country Name City State
United States Duke University Medical Center Pediatric Blood and Marrow Transplant Program Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the Feasibility of Attaining Acceptable Rates of Donor Cell Engraftment (>25% Donor Cells at 180 Days) Following RIC Regimens in Children < 21 Years Receiving UCBT for Non-malignant Disorders. Determine the feasibility of attaining acceptable rates of donor cell engraftment (>25% donor cells at 180 days) following reduced intensity conditioning regimens in children < 21 years receiving cord blood transplant for non-malignant disorders. 180 days post transplant No
Secondary To Describe the Pace of Neutrophil Recovery Neutrophil recovery was defined as the first day of an absolute neutrophil count (ANC) more than 500/uL for 3 consecutive days not secondary to granulocyte infusions 42 days post transplant No
Secondary To Evaluate the Pace of Immune Reconstitution. Immune reconstitution after RIC in UCBT was described. CD4 count is a standard measure of immune reconstitution and is described here. Additional data is available upon request. 1 year post transplant No
Secondary To Determine the Overall Survival at day180 Post-transplant To determine the overall survival at day180 post-transplant: determined by Kaplan Meier survival analysis 180 days No
Secondary To Describe Incidence of Acute Graft Versus Host Disease (GVHD) (II - IV) To describe incidence of acute Graft Versus Host Disease (GVHD) (II - IV) : measured by cumulative incidence analysis 100 days post transplant No
Secondary To Describe the Incidence of Grade 3-4 Organ Toxicity 2 years post transplant No
Secondary To Evaluate Long-term Complications, Such as Sterility, Endocrinopathy, and Growth Failure at least 2 years post transplant No
Secondary To Evaluate the Incidence of Late Graft Failures at 2 Years Post-transplant 2 years post transplant No
Secondary To Describe the Pace of Platelet Recovery Platelet engraftment was defined as the first day of platelet counts more than 50,000/uL for 7 consecutive days without transfusions 180 days post transplant No
See also
  Status Clinical Trial Phase
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT04614779 - Long-term Clinical Study of CN128 in Thalassemia Patients Phase 2
Completed NCT01158794 - Genes Influencing Iron Overload State
Recruiting NCT02995707 - The Effective and Safety of Thalidomide in NTDT Phase 2
Active, not recruiting NCT01935661 - A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients.
Terminated NCT01319851 - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation N/A
Completed NCT00901199 - Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload Phase 2
Terminated NCT00034528 - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Phase 2
Active, not recruiting NCT03655678 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia Phase 2/Phase 3
Recruiting NCT05508932 - Atrial Fibrillation in Beta-Thalassemia
Completed NCT03609827 - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed NCT03117192 - Zinc Supplementation on Cellular Immunity in Thalassemia Major Phase 4
Completed NCT03095326 - Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia Phase 4
Completed NCT01443312 - Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia
Completed NCT00235391 - Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Phase 3
Not yet recruiting NCT06058260 - Assessment of Cognitive Function and Quality of Life in Thalassemic Children at Sohag University Hospital
Completed NCT05529550 - Assessment of Nutritional Status and Role of Insulin-like Growth Factor-1 in Children
Completed NCT04582110 - The Role of OCTA in Patients Affected by Beta Thalassemia
Recruiting NCT06213402 - RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
Recruiting NCT01758042 - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders N/A